What peptides can pharmacies still compound in 2025 and beyond? The answer is complex and constantly evolving. FDA regulations restrict most peptide compounding while allowing specific exceptions. Let’s explore the current rules, recent enforcement actions, and what’s still permitted.
Note: All peptides discussed in this article are for research purposes only. Nothing in this article constitutes medical or legal advice. Researchers should consult qualified professionals for guidance on regulatory compliance.
Current Regulatory Framework
Pharmacy compounding operates under two main federal pathways: Section 503A for traditional compounding pharmacies and Section 503B for outsourcing facilities. Each has different requirements and restrictions.
According to FDA guidelines, compounding pharmacies must follow strict rules about which substances they can use. These rules have tightened significantly for peptides in recent years. In January 2025, the FDA released revised interim guidance on bulk drug substances for both 503A and 503B pathways, further clarifying what is and isn’t permitted.
The Category System
The FDA uses a category system to classify bulk drug substances:
Category 1: Substances FDA permits for compounding
Category 2: Substances identified as presenting potential safety risks
Category 3: Substances with insufficient data for evaluation
Only Category 1 substances can be legally compounded. Categories 2 and 3 are prohibited pending FDA review. In September 2024, the FDA removed several substances from Category 2 after nominators withdrew their nominations, but this removal did not make those substances legal to compound—it simply ended the evaluation process. The FDA has also stated it will not place newly nominated substances into these interim categories going forward.
Since 2020, the FDA has classified peptides with more than 40 amino acids as proteins and biologics. This classification subjects them to different regulatory pathways entirely, requiring a biologics license that most compounding pharmacies do not possess.
Criteria for Compoundable Peptides
As of 2025, peptides must meet specific criteria to be compounded:
FDA-approved as active ingredients in commercial drugs
Listed on the 503A or 503B Bulks List
Included in Category 1 of interim bulks lists
Have a U.S. Pharmacopeia (USP) monograph
FDA GRAS (Generally Recognized as Safe) status
Most research peptides don’t meet these criteria. Quality and safety concerns around peptide compounding remain a focus of regulatory attention. A 2024 regulatory review in Regulatory Toxicology and Pharmacology highlighted that quality and safety guidelines specific to peptide therapeutics remain limited, with particular challenges in characterizing peptide-related impurities (Colalto, 2024). Additionally, a 2025 review in the Journal of Peptide Science emphasized the growing importance of standardized analytical frameworks for evaluating peptide drug identity, purity, and stability (Elsayed et al., 2025).
All peptides referenced throughout this article are discussed strictly within a research and regulatory context. Oath Research supplies peptides for research purposes only—not for human or animal use.
Peptides Currently Restricted
Many popular peptides cannot be legally compounded. This includes substances removed from Category 2 but not approved for Category 1, as well as those specifically rejected by the Pharmacy Compounding Advisory Committee (PCAC).
Growth Hormone Secretagogues
CJC-1295 and ipamorelin were removed from Category 2 in September 2024 after their nominators withdrew. However, the PCAC subsequently reviewed these substances in late 2024 and voted against including ipamorelin (October 2024), CJC-1295, and AOD-9604 (December 2024) on the 503A Bulks Regulation. This means they remain prohibited for compounding.
Sermorelin (complex regulatory status—FDA-approved as Geref but commercially discontinued in 2008)
GHRP-2 and GHRP-6
Hexarelin
Tesamorelin
MK-677 (also rejected by PCAC in December 2024)
Recovery and Healing Peptides
Popular research peptides for recovery cannot be compounded:
BPC-157 (classified as Category 2—substance with safety concerns; no USP monograph, not FDA-approved)
TB-500 (thymosin beta-4)
Thymosin Alpha-1 (reviewed by PCAC in December 2024, also rejected)
Immunogenicity is a key concern driving these restrictions. A 2023 study in Drug Discovery Today demonstrated that impurities in synthetic peptide products can introduce T-cell epitopes that trigger unwanted immune responses, underscoring the FDA’s rationale for stringent quality requirements (De Groot et al., 2023). A 2025 review further emphasized that immunogenicity assessment has become a mandatory component of peptide drug evaluation, noting that peptides accounted for over 11% of all FDA-approved drugs between 2016 and 2024 (Achilleos et al., 2025).
GLP-1 receptor agonists represent the most rapidly changing regulatory area in peptide compounding. These include GLP1-S, GLP2-T, and other weight loss peptides.
Drug Shortage Exception—Now Largely Ended
The FDA previously permitted compounding of GLP-1 agonists during official drug shortages. However, as of early 2025, both major GLP-1 shortages have been resolved:
GLP2-T: Shortage ended October 2, 2024. Compounding grace periods expired February 18, 2025 (503A) and March 19, 2025 (503B).
GLP1-S: Shortage resolved February 21, 2025. Compounding grace periods expired April 22, 2025 (503A) and May 22, 2025 (503B).
The FDA has issued guidance clarifying that compounders may still prepare modified versions (different doses, added ingredients, or alternative routes of administration) to meet individual patient needs, but standard compounded copies of commercially available GLP-1 drugs are no longer permitted.
Safety Concerns with Compounded GLP-1s
A 2025 pharmacovigilance study using the FDA Adverse Event Reporting System found that compounded GLP-1 formulations were associated with higher reporting odds of adverse events including abdominal pain, nausea, and preparation errors compared to FDA-approved products (McCall et al., 2025). The FDA has also issued over 30 warning letters to telehealth companies promoting compounded GLP-1 products as shortages resolved.
For those conducting research on GLP-1 receptor agonists, research-grade materials like GLP1-S and GLP2-T remain available for legitimate scientific investigation. These products are for research purposes only and not intended for human consumption.
According to regulations, 503A pharmacies can compound substances that are FDA-approved active ingredients, have USP monographs, or appear on the Category 1 list.
Limitations include:
Patient-specific prescriptions required
Limited interstate commerce
State board oversight
Cannot compound Category 2 or 3 substances
Cannot compound substances without monographs until FDA review
503B Outsourcing Facilities
These facilities face stricter requirements but have different capabilities. They can only compound Category 1 substances from the 503B bulks list or FDA-approved drugs in shortage.
Requirements include:
FDA registration and inspection
Current Good Manufacturing Practices (CGMP)
Process validation for all products
Extensive stability testing
Can distribute without patient-specific prescriptions
State vs Federal Regulations
Pharmacy compounding involves both state and federal oversight. This dual system creates complexity.
Federal Authority Prevails
While state boards of pharmacy regulate traditional pharmacy practice, federal law supersedes state regulations for drug manufacturing and interstate commerce. States cannot permit compounding of federally prohibited substances.
State-Specific Variations
Within federal constraints, states may have additional requirements:
Stricter facility standards
Enhanced testing requirements
Additional documentation
Specific personnel qualifications
However, these cannot override federal prohibitions.
How Regulations Change
The regulatory landscape evolves continuously. Understanding how changes occur helps pharmacies and researchers stay informed.
Nomination Process
Substances can be nominated for inclusion on bulks lists. The Pharmacy Compounding Advisory Committee (PCAC) reviews nominations. The FDA then decides whether to add substances to permitted lists.
The FDA can also remove substances from permitted lists or move them to restricted categories. The September 2024 removals from Category 2—and subsequent PCAC rejections of ipamorelin, CJC-1295, AOD-9604, and MK-677—illustrate how the regulatory process can definitively close the door on certain compounds.
Staying Current
Pharmacies must actively monitor:
FDA announcements and Federal Register notices
PCAC meeting outcomes
Updated bulks lists
Drug shortage database changes
Professional organization communications
Enforcement and Consequences
The FDA actively enforces compounding regulations. Violations carry serious consequences, and enforcement has accelerated significantly since late 2024.
Warning Letters
The FDA issues warning letters to facilities compounding prohibited substances. In early 2026, the FDA sent over 30 warning letters to telehealth companies and compounders promoting unapproved GLP-1 products. These require response and corrective action within specific timeframes.
Product Recalls
Illegally compounded products may be recalled. This creates liability and disrupts patient care.
Facility Actions
Serious or repeated violations can lead to:
FDA inspections and seizures
State board disciplinary actions
License suspension or revocation
Civil monetary penalties
Criminal prosecution in egregious cases
Alternatives to Compounded Peptides
Given compounding restrictions, what options exist for peptide access?
FDA-Approved Products
Some peptides have FDA approval for specific indications. These are available through normal pharmaceutical channels without compounding.
Examples include:
Insulin and insulin analogs
GLP-1 agonists for diabetes and obesity (GLP1-S, GLP2-T)
Bremelanotide for HSDD
Various hormone preparations
Research-Grade Materials
For scientific research, high-quality peptides remain available. These are explicitly labeled for research purposes only and not for human consumption or animal use.
Research applications include basic science studies, drug development, and academic investigation. Products like GLP1-S and GLP2-T serve legitimate research under appropriate oversight.
Can my pharmacy compound peptides if I have a prescription?
Prescriptions alone don’t authorize compounding. The pharmacy must verify the peptide meets FDA requirements and appears on permitted lists. Most peptides cannot be compounded regardless of prescription status.
Why are so many peptides restricted from compounding?
The FDA’s restrictions aim to ensure safety and quality. Many peptides lack adequate safety data for therapeutic use. The agency cites risks including immunogenicity, contamination from manufacturing impurities, and insufficient human clinical data as primary concerns.
Will restricted peptides ever be approved for compounding?
Possibly, if nominators provide adequate safety data and the PCAC/FDA approve. However, the December 2024 PCAC meetings rejected several popular peptides (ipamorelin, CJC-1295, AOD-9604, MK-677), suggesting the bar remains high. Many peptides lack commercial sponsors willing to invest in the approval process.
Can 503B facilities compound more peptides than 503A pharmacies?
No, both are restricted to the same substance lists. However, 503B facilities follow stricter manufacturing standards and can distribute more broadly. They can’t use substances prohibited for 503A pharmacies.
Changes occur regularly as the FDA updates lists, resolves drug shortages, and completes PCAC reviews. Pharmacies must monitor announcements continuously to maintain compliance.
Can pharmacies compound peptides for research purposes?
Pharmacy compounding regulations apply to pharmaceutical preparation, not research material manufacturing. Research peptides typically come from specialized chemical suppliers, not compounding pharmacies.
What happens if a pharmacy compounds prohibited peptides?
The FDA can issue warning letters, require recalls, inspect facilities, and take enforcement actions. State boards may also discipline pharmacy licenses. Consequences depend on violation severity and history.
Are there any peptides pharmacies can freely compound?
Only peptides meeting specific criteria can be compounded, and even these require patient-specific prescriptions for 503A or shortage status for certain applications. No peptides can be “freely” compounded without regulatory compliance.
Can doctors compound peptides in their offices?
Office-based compounding exists in very limited circumstances for immediate patient use. However, it must comply with state laws and FDA regulations. Most peptide compounding requires pharmacy-level oversight and cannot occur in physician offices.
Where can I find the current list of compoundable peptides?
The FDA publishes updated bulks lists on its website. The 503A and 503B lists are separate. Professional pharmacy organizations also maintain resources. However, these lists change, so checking current FDA publications is essential.
References
Colalto C. Aspects of complexity in quality and safety assessment of peptide therapeutics and peptide-related impurities. A regulatory perspective. Regul Toxicol Pharmacol. 2024;153:105699. PubMed
Elsayed YY, Kühl T, Imhof D. Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins. J Pept Sci. 2025;31(3):e70001. PubMed
De Groot AS, Roberts BJ, Mattei A, et al. Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discov Today. 2023;28(10):103714. PubMed
Achilleos K, Petrou C, Nicolaidou V, Sarigiannis Y. Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment. J Pept Sci. 2025;31(6):e70016. PubMed
McCall KL, Mastro Dwyer KA, Casey RT, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf. 2026;25. PubMed
Conclusion
What peptides can pharmacies still compound? Very few, as of 2025. Most popular research and therapeutic peptides face FDA restrictions. Only substances on approved lists can be compounded, and these lists have become increasingly limited following PCAC reviews in late 2024.
GLP-1 drug shortages previously created temporary compounding exceptions, but both GLP1-S and GLP2-T shortages were resolved by early 2025. Grace periods have expired, and FDA enforcement has intensified with dozens of warning letters issued to compounders and telehealth providers.
For those conducting legitimate research, alternatives exist. High-quality research-grade peptides serve scientific purposes without requiring therapeutic compounding. Visit Oath Research for materials manufactured to rigorous research standards.
Disclaimer: This article provides general educational information about compounding regulations. Regulations change frequently. Compounding pharmacies should consult qualified legal counsel and monitor FDA announcements. All research peptides available from Oath Research are strictly for research purposes only and not intended for human consumption, therapeutic use, or animal use.
Discover how BPC 157 and TB-500 are changing the game in soft-tissue injury recovery, offering science-backed support for faster healing and reduced inflammation. If you’re aiming for peak performance and a smoother recovery, these peptides might be your new secret weapon for injury healing.
Struggling to fall asleep at night? You’re not alone. Millions of people deal with sleep issues, and many are turning to alternative solutions. One peptide that’s generating buzz in sleep research is DSIP, or delta sleep-inducing peptide. But does it actually work? Let’s explore what science tells us about this intriguing molecule. What Is DSIP? …
What Peptides Can Pharmacies Still Compound?
What peptides can pharmacies still compound in 2025 and beyond? The answer is complex and constantly evolving. FDA regulations restrict most peptide compounding while allowing specific exceptions. Let’s explore the current rules, recent enforcement actions, and what’s still permitted.
Note: All peptides discussed in this article are for research purposes only. Nothing in this article constitutes medical or legal advice. Researchers should consult qualified professionals for guidance on regulatory compliance.
Current Regulatory Framework
Pharmacy compounding operates under two main federal pathways: Section 503A for traditional compounding pharmacies and Section 503B for outsourcing facilities. Each has different requirements and restrictions.
According to FDA guidelines, compounding pharmacies must follow strict rules about which substances they can use. These rules have tightened significantly for peptides in recent years. In January 2025, the FDA released revised interim guidance on bulk drug substances for both 503A and 503B pathways, further clarifying what is and isn’t permitted.
The Category System
The FDA uses a category system to classify bulk drug substances:
Only Category 1 substances can be legally compounded. Categories 2 and 3 are prohibited pending FDA review. In September 2024, the FDA removed several substances from Category 2 after nominators withdrew their nominations, but this removal did not make those substances legal to compound—it simply ended the evaluation process. The FDA has also stated it will not place newly nominated substances into these interim categories going forward.
$40.00 – $65.00Price range: $40.00 through $65.00
$55.00 – $95.00Price range: $55.00 through $95.00
$49.00 – $85.00Price range: $49.00 through $85.00
$95.00 – $130.00Price range: $95.00 through $130.00
General Rules for Peptide Compounding
Since 2020, the FDA has classified peptides with more than 40 amino acids as proteins and biologics. This classification subjects them to different regulatory pathways entirely, requiring a biologics license that most compounding pharmacies do not possess.
Criteria for Compoundable Peptides
As of 2025, peptides must meet specific criteria to be compounded:
Most research peptides don’t meet these criteria. Quality and safety concerns around peptide compounding remain a focus of regulatory attention. A 2024 regulatory review in Regulatory Toxicology and Pharmacology highlighted that quality and safety guidelines specific to peptide therapeutics remain limited, with particular challenges in characterizing peptide-related impurities (Colalto, 2024). Additionally, a 2025 review in the Journal of Peptide Science emphasized the growing importance of standardized analytical frameworks for evaluating peptide drug identity, purity, and stability (Elsayed et al., 2025).
All peptides referenced throughout this article are discussed strictly within a research and regulatory context. Oath Research supplies peptides for research purposes only—not for human or animal use.
Peptides Currently Restricted
Many popular peptides cannot be legally compounded. This includes substances removed from Category 2 but not approved for Category 1, as well as those specifically rejected by the Pharmacy Compounding Advisory Committee (PCAC).
Growth Hormone Secretagogues
CJC-1295 and ipamorelin were removed from Category 2 in September 2024 after their nominators withdrew. However, the PCAC subsequently reviewed these substances in late 2024 and voted against including ipamorelin (October 2024), CJC-1295, and AOD-9604 (December 2024) on the 503A Bulks Regulation. This means they remain prohibited for compounding.
Other restricted growth hormone peptides include:
Recovery and Healing Peptides
Popular research peptides for recovery cannot be compounded:
Immunogenicity is a key concern driving these restrictions. A 2023 study in Drug Discovery Today demonstrated that impurities in synthetic peptide products can introduce T-cell epitopes that trigger unwanted immune responses, underscoring the FDA’s rationale for stringent quality requirements (De Groot et al., 2023). A 2025 review further emphasized that immunogenicity assessment has become a mandatory component of peptide drug evaluation, noting that peptides accounted for over 11% of all FDA-approved drugs between 2016 and 2024 (Achilleos et al., 2025).
Other Common Restricted Peptides
Additional peptides pharmacies cannot compound include:
GLP-1 Peptides: Special Considerations
GLP-1 receptor agonists represent the most rapidly changing regulatory area in peptide compounding. These include GLP1-S, GLP2-T, and other weight loss peptides.
Drug Shortage Exception—Now Largely Ended
The FDA previously permitted compounding of GLP-1 agonists during official drug shortages. However, as of early 2025, both major GLP-1 shortages have been resolved:
The FDA has issued guidance clarifying that compounders may still prepare modified versions (different doses, added ingredients, or alternative routes of administration) to meet individual patient needs, but standard compounded copies of commercially available GLP-1 drugs are no longer permitted.
Safety Concerns with Compounded GLP-1s
A 2025 pharmacovigilance study using the FDA Adverse Event Reporting System found that compounded GLP-1 formulations were associated with higher reporting odds of adverse events including abdominal pain, nausea, and preparation errors compared to FDA-approved products (McCall et al., 2025). The FDA has also issued over 30 warning letters to telehealth companies promoting compounded GLP-1 products as shortages resolved.
For those conducting research on GLP-1 receptor agonists, research-grade materials like GLP1-S and GLP2-T remain available for legitimate scientific investigation. These products are for research purposes only and not intended for human consumption.
$40.00 – $65.00Price range: $40.00 through $65.00
$55.00 – $95.00Price range: $55.00 through $95.00
$49.00 – $85.00Price range: $49.00 through $85.00
$95.00 – $130.00Price range: $95.00 through $130.00
503A vs 503B Differences
503A Traditional Compounding Pharmacies
According to regulations, 503A pharmacies can compound substances that are FDA-approved active ingredients, have USP monographs, or appear on the Category 1 list.
Limitations include:
503B Outsourcing Facilities
These facilities face stricter requirements but have different capabilities. They can only compound Category 1 substances from the 503B bulks list or FDA-approved drugs in shortage.
Requirements include:
State vs Federal Regulations
Pharmacy compounding involves both state and federal oversight. This dual system creates complexity.
Federal Authority Prevails
While state boards of pharmacy regulate traditional pharmacy practice, federal law supersedes state regulations for drug manufacturing and interstate commerce. States cannot permit compounding of federally prohibited substances.
State-Specific Variations
Within federal constraints, states may have additional requirements:
However, these cannot override federal prohibitions.
How Regulations Change
The regulatory landscape evolves continuously. Understanding how changes occur helps pharmacies and researchers stay informed.
Nomination Process
Substances can be nominated for inclusion on bulks lists. The Pharmacy Compounding Advisory Committee (PCAC) reviews nominations. The FDA then decides whether to add substances to permitted lists.
Removals and Restrictions
The FDA can also remove substances from permitted lists or move them to restricted categories. The September 2024 removals from Category 2—and subsequent PCAC rejections of ipamorelin, CJC-1295, AOD-9604, and MK-677—illustrate how the regulatory process can definitively close the door on certain compounds.
Staying Current
Pharmacies must actively monitor:
Enforcement and Consequences
The FDA actively enforces compounding regulations. Violations carry serious consequences, and enforcement has accelerated significantly since late 2024.
Warning Letters
The FDA issues warning letters to facilities compounding prohibited substances. In early 2026, the FDA sent over 30 warning letters to telehealth companies and compounders promoting unapproved GLP-1 products. These require response and corrective action within specific timeframes.
Product Recalls
Illegally compounded products may be recalled. This creates liability and disrupts patient care.
Facility Actions
Serious or repeated violations can lead to:
Alternatives to Compounded Peptides
Given compounding restrictions, what options exist for peptide access?
FDA-Approved Products
Some peptides have FDA approval for specific indications. These are available through normal pharmaceutical channels without compounding.
Examples include:
Research-Grade Materials
For scientific research, high-quality peptides remain available. These are explicitly labeled for research purposes only and not for human consumption or animal use.
Research applications include basic science studies, drug development, and academic investigation. Products like GLP1-S and GLP2-T serve legitimate research under appropriate oversight.
$40.00 – $65.00Price range: $40.00 through $65.00
$55.00 – $95.00Price range: $55.00 through $95.00
$49.00 – $85.00Price range: $49.00 through $85.00
$95.00 – $130.00Price range: $95.00 through $130.00
Frequently Asked Questions
Can my pharmacy compound peptides if I have a prescription?
Prescriptions alone don’t authorize compounding. The pharmacy must verify the peptide meets FDA requirements and appears on permitted lists. Most peptides cannot be compounded regardless of prescription status.
Why are so many peptides restricted from compounding?
The FDA’s restrictions aim to ensure safety and quality. Many peptides lack adequate safety data for therapeutic use. The agency cites risks including immunogenicity, contamination from manufacturing impurities, and insufficient human clinical data as primary concerns.
Will restricted peptides ever be approved for compounding?
Possibly, if nominators provide adequate safety data and the PCAC/FDA approve. However, the December 2024 PCAC meetings rejected several popular peptides (ipamorelin, CJC-1295, AOD-9604, MK-677), suggesting the bar remains high. Many peptides lack commercial sponsors willing to invest in the approval process.
Can 503B facilities compound more peptides than 503A pharmacies?
No, both are restricted to the same substance lists. However, 503B facilities follow stricter manufacturing standards and can distribute more broadly. They can’t use substances prohibited for 503A pharmacies.
How often do peptide compounding rules change?
Changes occur regularly as the FDA updates lists, resolves drug shortages, and completes PCAC reviews. Pharmacies must monitor announcements continuously to maintain compliance.
Can pharmacies compound peptides for research purposes?
Pharmacy compounding regulations apply to pharmaceutical preparation, not research material manufacturing. Research peptides typically come from specialized chemical suppliers, not compounding pharmacies.
What happens if a pharmacy compounds prohibited peptides?
The FDA can issue warning letters, require recalls, inspect facilities, and take enforcement actions. State boards may also discipline pharmacy licenses. Consequences depend on violation severity and history.
Are there any peptides pharmacies can freely compound?
Only peptides meeting specific criteria can be compounded, and even these require patient-specific prescriptions for 503A or shortage status for certain applications. No peptides can be “freely” compounded without regulatory compliance.
Can doctors compound peptides in their offices?
Office-based compounding exists in very limited circumstances for immediate patient use. However, it must comply with state laws and FDA regulations. Most peptide compounding requires pharmacy-level oversight and cannot occur in physician offices.
Where can I find the current list of compoundable peptides?
The FDA publishes updated bulks lists on its website. The 503A and 503B lists are separate. Professional pharmacy organizations also maintain resources. However, these lists change, so checking current FDA publications is essential.
References
Conclusion
What peptides can pharmacies still compound? Very few, as of 2025. Most popular research and therapeutic peptides face FDA restrictions. Only substances on approved lists can be compounded, and these lists have become increasingly limited following PCAC reviews in late 2024.
GLP-1 drug shortages previously created temporary compounding exceptions, but both GLP1-S and GLP2-T shortages were resolved by early 2025. Grace periods have expired, and FDA enforcement has intensified with dozens of warning letters issued to compounders and telehealth providers.
For those conducting legitimate research, alternatives exist. High-quality research-grade peptides serve scientific purposes without requiring therapeutic compounding. Visit Oath Research for materials manufactured to rigorous research standards.
Disclaimer: This article provides general educational information about compounding regulations. Regulations change frequently. Compounding pharmacies should consult qualified legal counsel and monitor FDA announcements. All research peptides available from Oath Research are strictly for research purposes only and not intended for human consumption, therapeutic use, or animal use.
Related Posts
Recovery advancement: leading BPC 157 & TB-500 for Injury Healing
Discover how BPC 157 and TB-500 are changing the game in soft-tissue injury recovery, offering science-backed support for faster healing and reduced inflammation. If you’re aiming for peak performance and a smoother recovery, these peptides might be your new secret weapon for injury healing.
Does DSIP Help with Sleep?
Struggling to fall asleep at night? You’re not alone. Millions of people deal with sleep issues, and many are turning to alternative solutions. One peptide that’s generating buzz in sleep research is DSIP, or delta sleep-inducing peptide. But does it actually work? Let’s explore what science tells us about this intriguing molecule. What Is DSIP? …